首页 | 本学科首页   官方微博 | 高级检索  
检索        

脂联素对高脂饮食诱导的胰岛素抵抗子宫内膜癌裸鼠移植瘤生长的影响
引用本文:何珊,邓露,蔡志福,张洁清,李力.脂联素对高脂饮食诱导的胰岛素抵抗子宫内膜癌裸鼠移植瘤生长的影响[J].中国癌症防治杂志,2020,12(2):186-190.
作者姓名:何珊  邓露  蔡志福  张洁清  李力
作者单位:广西医科大学附属肿瘤医院妇瘤科, 邵阳市中心医院影像科
基金项目:广西自然科学基金项目(2015GXNSFAA139127);北京医卫健康公益基金项目(YWJKJJHKYJJ-B17410-B06);广西区域性高发肿瘤早期防治研究重点实验室课题(GK2015-ZZ08);广西临床重点专科建设项目(2018-3-9)。
摘    要:目的 探讨脂联素对高脂饮食诱导裸鼠胰岛素抵抗子宫内膜癌移植瘤生长的影响。方法 40只裸鼠随机分成高脂组和普食组,每组20只,分别喂养高脂饲料(high-fat diet,HFD)和普通饲料(normal diet,ND),10周后测定裸鼠空腹血糖(fasting blood glucose,FBG)和空腹血胰岛素(fasting serum insulin,FINS)水平,计算胰岛素抵抗指数(HOMA-IR),建立胰岛素抵抗裸鼠模型。第11周接种子宫内膜癌HEC-1B细胞,待瘤体长至0.5 cm时,两组随机选取10只裸鼠腹腔注射脂联素(adiponectin,APN)分为HFD+APN组、ND+APN组;其余裸鼠分别注射0.9%氯化钠分为HFD组、ND组;14周后,测定各组血糖和血脂的代谢情况。结果 高脂组裸鼠10周后的平均体重、体长、FBG、FINS、HOMA-IR均大于普食组,糖耐量试验和胰岛素耐量试验结果显示血糖水平亦高于普食组(均P<0.05);接种子宫内膜癌HEC-1B细胞后均成瘤,建模成功。HFD+APN组和ND+APN组移植瘤平均重量和体积增长速度均分别低于HFD组和ND组(均P<0.05)。HFD组和HFD+APN组14周后的FINS、HOMA-IR、TC和TG均较ND组和ND+APN明显升高(均P<0.01),且HFD组明显高于HFD+APN组(均P<0.01);HFD+APN组的血脂联素水平低于ND+APN组(P<0.01),HFD组则低于ND组(P<0.05)。结论 脂联素可改善高脂饮食导致的胰岛素抵抗,抑制子宫内膜癌移植瘤生长。

关 键 词:子宫内膜癌  脂联素  胰岛素抵抗  移植瘤

Effect of adiponectin on the growth of insulin resistance endometrial cancer xenografts in nude mice induced by high-fat diet
HE Shan,DENG Lu,CAI Zhifu,ZHANG Jieqing,LI Li.Effect of adiponectin on the growth of insulin resistance endometrial cancer xenografts in nude mice induced by high-fat diet[J].Chinese Journal of Oncology Prevention and Treatment,2020,12(2):186-190.
Authors:HE Shan  DENG Lu  CAI Zhifu  ZHANG Jieqing  LI Li
Institution:Department of Gynecologic Oncology,Guangxi Medical University Cancer Hospital, Department of Radiology,The Central Hospital of Shaoyang
Abstract:Objective To investigate the effect of adiponectin on the growth of insulin resistance endometrial cancer xenografts in nude mice induced by high-fat diet. Methods Forty nude mice were randomly divided into a high-fat diet group and a normal diet group,with20 rats in each group,which were fed with high-fat diet(HFD) and normal diet(ND),respectively. The levels of fasting blood glucose(FBG)and fasting serum insulin(FINS)in nude mice after feeding 10 weeks were measured,and the insulin resistance index(HOMA-IR)was calculated,resulting in a model of insulin resistance in nude mice. At the 11 th week,endometrial cancer HEC-1B cells were inoculated into nude mice. After the xenografts reached 0.5 cm,10 nude mice were randomly selected from each group,named as HFD+APN group and ND+APN group,respectively,and adiponectin was intraperitoneally injected into nude mice;the remaining nude mice,named HFD group and ND group,respectively,were injected with 0.9% sodium chloride. After 14 weeks,the metabolism of blood glucose and blood lipids in each group was measured. Results The average body weight,body length,FBG,FINS,and HOMA-IR of nude mice in the highfat diet group after feeding 10 weeks were larger than those in the normal diet group,and the results of glucose tolerance test and insulin tol erance test showed that the blood glucose level was also higher than that in the normal diet group(all P<0.05). Nude mice formed tumors after inoculation with endometrial cancer HEC-1B cells,and the modeling was successful. The average weight and volume growth rate of xenografts in the HFD+APN group and the ND+APN group were lower than those in the HFD group and the ND group(all P<0.05). After14 weeks,the level of FINS,HOMA-IR,TC and TG of the HFD group and the HFD+APN group were all higher than those of the ND group and the ND+APN group(all P<0.01),and the HFD group was significantly higher than the HFD+APN group(P<0.01). Serum adiponectin level in the HFD+APN group was significantly lower than that in the ND+APN group(P<0.01),and the HFD group was also significantly lower than the ND group(P<0.05). Conclusion Adiponectin can improve insulin resistance caused by a high-fat diet,inhibiting the growth of endometrial cancer xenografts.
Keywords:Endometrial cancer  Adiponectin  Insulin resistance  Xenograft
本文献已被 维普 等数据库收录!
点击此处可从《中国癌症防治杂志》浏览原始摘要信息
点击此处可从《中国癌症防治杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号